D. Luke Fischer, Lea T. Grinberg, Jared T. Ahrendsen, Thomas G. Beach, Kevin F. Bieniek, Rudolph J. Castellani, Rati Chkheidze, Inma Cobos, Mark Cohen, John F. Crary, Dennis W. Dickson, Brittany N. Dugger, Sara R. Dunlop, Kurt Farrell, Bernardino Ghetti, Mohammad Haeri, William Harrison, Elizabeth Head, Annie Hiniker, Eric J. Huang, Anita Huttner, Pouya Jamshidi, Alifiya Kapasi, C. Dirk Keene, Julia Kofler, Caitlin S. Latimer, Ann C. McKee, Karin Mente, Michael B. Miller, Thomas J. Montine, Meaghan Morris, Melissa E. Murray, Peter T. Nelson, Kathy L. Newell, Richard J. Perrin, Biswarathan Ramani, R. Ross Reichard, Subhojit Roy, Johannes C. M. Schlachetzki, William W. Seeley, Geidy E. Serrano, Salvatore Spina, Andrew F. Teich, Shih-Hsiu J. Wang, Thomas Wisniewski, Edward B. Lee
{"title":"Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers","authors":"D. Luke Fischer, Lea T. Grinberg, Jared T. Ahrendsen, Thomas G. Beach, Kevin F. Bieniek, Rudolph J. Castellani, Rati Chkheidze, Inma Cobos, Mark Cohen, John F. Crary, Dennis W. Dickson, Brittany N. Dugger, Sara R. Dunlop, Kurt Farrell, Bernardino Ghetti, Mohammad Haeri, William Harrison, Elizabeth Head, Annie Hiniker, Eric J. Huang, Anita Huttner, Pouya Jamshidi, Alifiya Kapasi, C. Dirk Keene, Julia Kofler, Caitlin S. Latimer, Ann C. McKee, Karin Mente, Michael B. Miller, Thomas J. Montine, Meaghan Morris, Melissa E. Murray, Peter T. Nelson, Kathy L. Newell, Richard J. Perrin, Biswarathan Ramani, R. Ross Reichard, Subhojit Roy, Johannes C. M. Schlachetzki, William W. Seeley, Geidy E. Serrano, Salvatore Spina, Andrew F. Teich, Shih-Hsiu J. Wang, Thomas Wisniewski, Edward B. Lee","doi":"10.1002/alz.70734","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Our understanding of Alzheimer's disease (AD) and related dementias (ADRD) has grown exponentially, thanks to significant investments by the National Institute on Aging (NIA). This article celebrates the 40th anniversary of the NIA's Alzheimer's Disease Research Centers, highlighting the pivotal role of neuropathology as the bedrock for neurodegeneration research. Neuropathology has championed the key principles of proteinopathy, selective vulnerability, and stereotypic spread. Furthermore, neuropathologic studies advanced our understanding of ADRD prevalence, heterogeneity, clinical–pathological correlations, and genetic underpinnings, spurring biomarker development for target engagement and disease monitoring. Disease-modifying therapies for AD were inspired and informed by neuropathology. The neuropathology community is poised to refine diagnostics, leveraging digital pathology and integrating genetics and pathomics to enhance subtyping for novel precision medicine approaches. Despite some common misconceptions and logistical challenges, neuropathology continues to be a critical component of the ADRD research infrastructure, serving as a key bridge between allied basic and clinical sciences.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>We celebrate 40 years of NIA-funded ADRCs and their contributions through neuropathology studies that have significantly advanced our understanding and treatment of ADRD.</li>\n \n <li>Neuropathology uncovers principles of neurodegenerative disease: proteinopathy, selective vulnerability, and stereotypic spread, informing diagnostics and therapies.</li>\n \n <li>Development of AD biomarkers with reference to neuropathology enhances accuracy in diagnosis and monitoring, paving the way for targeted disease-modifying therapies.</li>\n \n <li>Integration of digital pathology, genetics, and novel tools in neurodegeneration research promises advanced precision medicine approaches and refined diagnostics.</li>\n \n <li>Misconceptions and logistical challenges to neuropathological research are addressed to improve understanding and collaboration.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 10","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70734","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70734","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Our understanding of Alzheimer's disease (AD) and related dementias (ADRD) has grown exponentially, thanks to significant investments by the National Institute on Aging (NIA). This article celebrates the 40th anniversary of the NIA's Alzheimer's Disease Research Centers, highlighting the pivotal role of neuropathology as the bedrock for neurodegeneration research. Neuropathology has championed the key principles of proteinopathy, selective vulnerability, and stereotypic spread. Furthermore, neuropathologic studies advanced our understanding of ADRD prevalence, heterogeneity, clinical–pathological correlations, and genetic underpinnings, spurring biomarker development for target engagement and disease monitoring. Disease-modifying therapies for AD were inspired and informed by neuropathology. The neuropathology community is poised to refine diagnostics, leveraging digital pathology and integrating genetics and pathomics to enhance subtyping for novel precision medicine approaches. Despite some common misconceptions and logistical challenges, neuropathology continues to be a critical component of the ADRD research infrastructure, serving as a key bridge between allied basic and clinical sciences.
Highlights
We celebrate 40 years of NIA-funded ADRCs and their contributions through neuropathology studies that have significantly advanced our understanding and treatment of ADRD.
Neuropathology uncovers principles of neurodegenerative disease: proteinopathy, selective vulnerability, and stereotypic spread, informing diagnostics and therapies.
Development of AD biomarkers with reference to neuropathology enhances accuracy in diagnosis and monitoring, paving the way for targeted disease-modifying therapies.
Integration of digital pathology, genetics, and novel tools in neurodegeneration research promises advanced precision medicine approaches and refined diagnostics.
Misconceptions and logistical challenges to neuropathological research are addressed to improve understanding and collaboration.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
